Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2006

Open Access 01-12-2006 | Research article

Understanding and meeting the needs of those using growth hormone injection devices

Authors: Hervé Dumas, Paris Panayiotopoulos, Dorothy Parker, Vincent Pongpairochana

Published in: BMC Endocrine Disorders | Issue 1/2006

Login to get access

Abstract

Background

Recombinant human growth hormone (r-hGH) is used to treat: growth hormone deficiency in children and adults; children born small for gestational age; Turner's syndrome; and chronic renal failure. r-hGH is administered by daily subcutaneous injection and may be given using a number of different administration devices. The aim of this survey was, firstly, to identify which attributes of an r-hGH administration device are considered most important to physicians, teenage patients, parents of young children requiring GH and nurses who have experience of r-hGH administration, and, secondly, to determine how they rate existing devices in each of these key attributes.

Methods

The opinions of 67 individuals with experience in r-hGH administration were captured in discussion sessions. Parents, physicians and nurses were asked to rate 19 device attributes by completing a questionnaire, and to rank four different r-hGH administration devices (including a conceptual electronic device) in order of preference.

Results

Reliability, ease of use, lack of pain during injection, safety in use, storage, and number of steps in preparation before use, during use and after were considered to be the five most desirable attributes of an r-hGH administration device. An electronic device was preferred to an automatic, multi-dose injection device, a needle-free injection device or a manual, ready-to-use, disposable injection device.

Conclusion

In the opinion of physicians, nurses and parents using r-hGH injection devices, an ideal device must combine reliability with simplicity, while delivering treatment with minimal pain. An electronic device, which combines many of the most useful features of existing devices with novel functions, was the preferred option for r-hGH administration.
Appendix
Available only for authorised users
Literature
1.
go back to reference Preece MA: Diagnosis and treatment of children with growth hormone deficiency. Clinical Endocrinology and Metabolism. 1982, 11 (1): 1–24-CrossRef Preece MA: Diagnosis and treatment of children with growth hormone deficiency. Clinical Endocrinology and Metabolism. 1982, 11 (1): 1–24-CrossRef
2.
go back to reference McGauley G: The psychological consequences and quality of life in adults with growth hormone deficiency. Growth Hormone and IGF Research. 2000, 10 Suppl B: S63–S68-PubMed McGauley G: The psychological consequences and quality of life in adults with growth hormone deficiency. Growth Hormone and IGF Research. 2000, 10 Suppl B: S63–S68-PubMed
3.
go back to reference McCallum RW, Petrie JR, Dominiczak AF, Connell JM: Growth hormone deficiency and vascular risk. Clinical Endocrinology. 2002, 57 (1): 11–24-10.1046/j.1365-2265.2002.01559.x.CrossRefPubMed McCallum RW, Petrie JR, Dominiczak AF, Connell JM: Growth hormone deficiency and vascular risk. Clinical Endocrinology. 2002, 57 (1): 11–24-10.1046/j.1365-2265.2002.01559.x.CrossRefPubMed
4.
go back to reference Raben MS: Treatment of a pituitary dwarf with human growth hormone. Journal of Clinical Endocrinology and Metabolism. 1958, 18 (8): 901–903-CrossRefPubMed Raben MS: Treatment of a pituitary dwarf with human growth hormone. Journal of Clinical Endocrinology and Metabolism. 1958, 18 (8): 901–903-CrossRefPubMed
5.
go back to reference Verhelst J, Abs R, Vandeweghe M, Mockel J, Legros JJ, Copinschi G, Mahler C, Velkeniers B, Vanhaelst L, Van Aelst A, De Rijdt D, Stevenaert A, Beckers A: Two years of replacement therapy in adults with growth hormone deficiency. Clinical Endocrinology. 1997, 47 (4): 485–494-10.1046/j.1365-2265.1997.3041112.x.CrossRefPubMed Verhelst J, Abs R, Vandeweghe M, Mockel J, Legros JJ, Copinschi G, Mahler C, Velkeniers B, Vanhaelst L, Van Aelst A, De Rijdt D, Stevenaert A, Beckers A: Two years of replacement therapy in adults with growth hormone deficiency. Clinical Endocrinology. 1997, 47 (4): 485–494-10.1046/j.1365-2265.1997.3041112.x.CrossRefPubMed
6.
go back to reference Johnson RT, Gibbs CJJ: Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. New England Journal of Medicine. 1998, 339 (27): 1994–2004-10.1056/NEJM199812313392707.CrossRefPubMed Johnson RT, Gibbs CJJ: Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. New England Journal of Medicine. 1998, 339 (27): 1994–2004-10.1056/NEJM199812313392707.CrossRefPubMed
7.
go back to reference Flodh H: Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatrica Scandinavica. 1986, 325: 1–9-PubMed Flodh H: Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatrica Scandinavica. 1986, 325: 1–9-PubMed
8.
go back to reference Zeisel HJ, von Petrykowski W, Wais U: Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. Hormone Research. 1992, 37 (Suppl 2): 5–13- Zeisel HJ, von Petrykowski W, Wais U: Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. Hormone Research. 1992, 37 (Suppl 2): 5–13-
9.
go back to reference Plotnick L, Attie KM, Blethen SL, Sy JP: Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience. Pediatrics. 1998, 102 (2 Pt 3): 479–481-PubMed Plotnick L, Attie KM, Blethen SL, Sy JP: Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience. Pediatrics. 1998, 102 (2 Pt 3): 479–481-PubMed
10.
go back to reference Fine RN, Kohaut EC, Brown D, Perlman AJ: Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. Journal of Pediatrics. 1994, 124 (3): 374–382-CrossRefPubMed Fine RN, Kohaut EC, Brown D, Perlman AJ: Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. Journal of Pediatrics. 1994, 124 (3): 374–382-CrossRefPubMed
11.
go back to reference Dahlgren J, Wikland KA: Final height in short children born small for gestational age treated with growth hormone. Pediatric Research. 2005, 57 (2): 216–222-CrossRefPubMed Dahlgren J, Wikland KA: Final height in short children born small for gestational age treated with growth hormone. Pediatric Research. 2005, 57 (2): 216–222-CrossRefPubMed
12.
go back to reference Smith SL, Hindmarsh PC, Brook CG: Compliance with growth hormone treatment – are they getting it?. Archives of Disease in Childhood. 1993, 68 (1): 91–93-PubMedPubMedCentral Smith SL, Hindmarsh PC, Brook CG: Compliance with growth hormone treatment – are they getting it?. Archives of Disease in Childhood. 1993, 68 (1): 91–93-PubMedPubMedCentral
13.
go back to reference Jorgensen JO, Mooller J, Jensen FS, Joorgensen JT, Christiansen JS: Growth hormone administration by means of an injection pen. Pharmacology and Toxicology. 1989, 65 (2): 96–99-CrossRefPubMed Jorgensen JO, Mooller J, Jensen FS, Joorgensen JT, Christiansen JS: Growth hormone administration by means of an injection pen. Pharmacology and Toxicology. 1989, 65 (2): 96–99-CrossRefPubMed
14.
15.
go back to reference Stanhope R, Albanese A, Moyle L, Hamill G: Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system. Archives of Disease in Childhood. 1992, 67 (8): 994–997-CrossRefPubMedPubMedCentral Stanhope R, Albanese A, Moyle L, Hamill G: Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system. Archives of Disease in Childhood. 1992, 67 (8): 994–997-CrossRefPubMedPubMedCentral
16.
go back to reference Sjoblom K, Albertsson-Wikland K, Bengtsson BA, Johannsson G, Thoren M, Degerblad M, Savage MO: Patient evaluation of a new injection pen for growth hormone treatment in children and adults. Acta Paediatrica. 1995, 411: 63–65-PubMed Sjoblom K, Albertsson-Wikland K, Bengtsson BA, Johannsson G, Thoren M, Degerblad M, Savage MO: Patient evaluation of a new injection pen for growth hormone treatment in children and adults. Acta Paediatrica. 1995, 411: 63–65-PubMed
17.
go back to reference Verhagen A, Ebels JT, Dogterom AA, Jonkman JH: Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection. European Journal of Clinical Pharmacology. 1995, 49 (1-2): 69–72-10.1007/BF00192361.CrossRefPubMed Verhagen A, Ebels JT, Dogterom AA, Jonkman JH: Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection. European Journal of Clinical Pharmacology. 1995, 49 (1-2): 69–72-10.1007/BF00192361.CrossRefPubMed
18.
go back to reference Bareille P, MacSwiney M, Albanese A, De Vile C, Stanhope R: Growth hormone treatment without a needle using the Preci-Jet 50 transjector. Archives of Disease in Childhood. 1997, 76 (1): 65–67-CrossRefPubMedPubMedCentral Bareille P, MacSwiney M, Albanese A, De Vile C, Stanhope R: Growth hormone treatment without a needle using the Preci-Jet 50 transjector. Archives of Disease in Childhood. 1997, 76 (1): 65–67-CrossRefPubMedPubMedCentral
19.
go back to reference Verrips GH, Hirasing RA, Fekkes M, Vogels T, Verloove-Vanhorick SP, Delemarre-Van de Waal HA: Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy. Acta Paediatrica. 1998, 87 (2): 154–158-10.1080/08035259850157589.CrossRefPubMed Verrips GH, Hirasing RA, Fekkes M, Vogels T, Verloove-Vanhorick SP, Delemarre-Van de Waal HA: Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy. Acta Paediatrica. 1998, 87 (2): 154–158-10.1080/08035259850157589.CrossRefPubMed
20.
go back to reference Silverstein JH, Murray FT, Malasanos T, Myers S, Johnson SB, Frye K, Grossman M: Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children. Endocrine. 2001, 15 (1): 15–17-10.1385/ENDO:15:1:015.CrossRefPubMed Silverstein JH, Murray FT, Malasanos T, Myers S, Johnson SB, Frye K, Grossman M: Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children. Endocrine. 2001, 15 (1): 15–17-10.1385/ENDO:15:1:015.CrossRefPubMed
21.
go back to reference Dorr HG, Zabransky S, Keller E, Otten BJ, Partsch CJ, Nyman L, Gillespie BK, Lester NR, Wilson AM, Hyren C, van Kuijck MA, Schuld P, Schoenfeld SL: Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. Journal of Pediatric Endocrinology and Metabolism. 2003, 16 (3): 383–392-CrossRefPubMed Dorr HG, Zabransky S, Keller E, Otten BJ, Partsch CJ, Nyman L, Gillespie BK, Lester NR, Wilson AM, Hyren C, van Kuijck MA, Schuld P, Schoenfeld SL: Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. Journal of Pediatric Endocrinology and Metabolism. 2003, 16 (3): 383–392-CrossRefPubMed
22.
go back to reference Chan H: Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. Journal of Advanced Nursing. 2001, 35 (6): 882–892-10.1046/j.1365-2648.2001.01925.x.CrossRefPubMed Chan H: Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin. Journal of Advanced Nursing. 2001, 35 (6): 882–892-10.1046/j.1365-2648.2001.01925.x.CrossRefPubMed
Metadata
Title
Understanding and meeting the needs of those using growth hormone injection devices
Authors
Hervé Dumas
Paris Panayiotopoulos
Dorothy Parker
Vincent Pongpairochana
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2006
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-6-5

Other articles of this Issue 1/2006

BMC Endocrine Disorders 1/2006 Go to the issue